ArticleThe clinical respiratory journal2025
Extracellular Matrix and Endothelial Activation Markers in the Bronchial and Pulmonary Arteries in COPD.
Article in The clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The "two-hit" storm: a hyper-inflammatory endotype in pediatric long COVID and its role in the severity of secondary bacterial pneumonia-a mechanistic review and clinical implications.Frontiers in public health · 2026Review
- Extracellular Matrix and Endothelial Activation Markers in the Bronchial and Pulmonary Arteries in COPD.The clinical respiratory journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundVascular alterations contribute significantly to the chronic obstructive pulmonary disease (COPD) pathophysiology. Thirty-nine percent of patients with COPD develop pulmonary hypertension, especially patients with the severe form of the disease. Cigarette-induced endothelial dysfunction is important in the pathogenesis of vascular alterations, even in the mild forms of the disease. This study investigates extracellular matrix (ECM) remodelling and endothelial activation in pulmonary (PMA) and bronchial muscular arteries (BMA) from non-smokers (NS), nonobstructed smokers (NOS) and patients with mild/moderate COPD.
methodsLung tissue samples from 44 patients undergoing lung resection were analysed. Morphometric parameters, ECM components (collagens, fibronectin, elastic fibres, tenascin-C and versican) and endothelial markers (VCAM-1, ICAM-1 and endothelin-1) were quantified in BMA and PMA using immunohistochemistry and morphometric analysis. Group differences and correlations with clinical parameters were assessed.
resultsCOPD patients showed increased intimal thickness and fibronectin deposition in PMA, and larger adventitial areas in BMA compared to NS. NOS exhibited higher VCAM-1 expression in BMA and increased elastic fibre content in PMA. In COPD, elastic fibres and type-III collagen negatively correlated with smoking history (pack-years), while fibronectin positively correlated with age. VCAM-1 expression in BMA correlated negatively with lung function (FEV
conclusionsThis study demonstrates for the first time ECM remodelling and endothelial activation in bronchial arteries of smokers and patients with COPD. Fibronectin emerges as a key ECM component in arterial remodelling in mild-moderate COPD. Understanding vascular changes may provide new insights into the regulation of bronchial circulation and the development of pulmonary hypertension in COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.